E. Lelievre

Servier (France)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

C. Piraube

Servier (France)

Christophe Créminon

Commissariat à l'Énergie Atomique et aux Énergies Alternatives

Ben Robinson

Pfizer (United States)

B. Gordon

Klinik und Poliklinik für Urologie

P. Génissel

Institut des Hautes Études Scientifiques

H.E. English

Servier (United Kingdom)

Xavier Morge

Commissariat à l'Énergie Atomique et aux Énergies Alternatives

Norbert Bromet

Centre de Biophysique Moléculaire

Gilles Simonin

Servier (France)

Claire Boursier-Neyret

Laboratoire de Mathématiques Analyse, Probabilités, Modélisation Orléans

Cooperative Institutions

Servier (France)

Inserm

Commissariat à l'Énergie Atomique et aux Énergies Alternatives

CEA Paris-Saclay

Servier (United Kingdom)

Institut des Hautes Études Scientifiques

Laboratoire de Mathématiques Analyse, Probabilités, Modélisation Orléans

Centre National de la Recherche Scientifique

Institut de Biologie et Technologies

Direction des énergies

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Determination of melatonin in biological fluids in the presence of the melatonin agonist S 20098: comparison of immunological techniques and GC-MS methods

Journal of Pharmaceutical and Biomedical Analysis (1999)

Gilles Simonin Laurence Bru E. Lelievre Jean-Philippe Jeanniot Norbert Bromet

Solid phase extraction

Matrix (chemical analysis)

Biological fluids

10.1016/s0731-7085(99)00150-8

Cite

Citations (48)

Enzyme Immunoassays for a New Angiotensin-Converting Enzyme Inhibitor, Zabicipril, and Its Active Metabolite in Human Plasma

Therapeutic Drug Monitoring (1993)

Éric Ezan Xavier Morge E. Lelievre Christophe Créminon C. Piraube

Zabicipril (S 9650) is a new angiotensin-converting enzyme inhibitor whose hydrolysis in vivo produces the pharmacologically active metabolite zabiciprilat (S 10211). Two competitive enzyme immunoassays specific for either zabicipril or zabiciprilat have been developed using acetylcholinesterase (E.C. 3.1.1.7) as label. Antibodies were raised in rabbits after immunization with lysil derivatives of zabicipril or zabiciprilat coupled with bovine serum albumin. Assays were performed in 96-well microtiter plates coated with a monoclonal antibody raised against rabbit immunoglobulin G, thus ensuring rapid separation of free and bound fractions of the tracer. The analysis does not require any extraction step. In the case of the assay of zabiciprilat, interference generated by endogenous angiotensin-converting enzyme (ACE) was eliminated by the addition of perindoprilat, another ACE inhibitor. Perindoprilat was not recognized by the antibodies (cross-reactivity <0.01%) and did not affect assay efficiency. The specificity of the assays was checked by high-performance liquid chromatography of human plasma samples obtained after oral administration of 2 mg of zabicipril. No metabolites or endogenous substances were detected. The mean reproducibility was 15% for the assay of zabicipril and 19% for the assay of zabiciprilat. The quantification limits were 1.2 ng/ml for the zabicipril assay and 0.8 ng/ml for the zabiciprilat assay. These assays are therefore suitable for pharmacokinetic studies and drug monitoring in clinical studies.

Active metabolite

10.1097/00007691-199310000-00015

Cite

Citations (5)

Radioimmunoassay for the measurement of S9788 in serum and microdialysis samples

Journal of Pharmaceutical and Biomedical Analysis (1997)

Claire Mackie H.E. English E. Lelievre B. Gordon P. Génissel

Microdialysis

Quantitative Analysis

Standard curve

10.1016/s0731-7085(96)01924-3

Cite